ALK and lung carcinoma: The potential role of alternative ADCs targeting the human trophoblast cell‐surface antigen 2 (TROP2) (NCT04152499) and MET351, 352 (NCT03859752) is also being evaluated in patients with lung cancers, potentially including NSCLCs with EGFR mutations or ALK rearrangements.